Competition for Early-Line Biologic Use among Psoriasis Patients Intensifies ... - MarketWatch (press release)

Competition for Early-Line Biologic Use among disease of the skin Patients Intensifies ... MarketWatch (press release) According to new analysis of United States of America patient-level claims data, spell Enbrel remains the most commonly used biologic in the treatment of disease of the skin , Humira continues to see sustained quarter-over-quarter ingestion among recently treated disease of the skin patients, ... and more » Link To Article